Overview
癌症：英文版, published by BMC, published 689 papers in 2021–2025, and these papers have received 24,921 citations so far. Its h-index is 125 and its two-year mean citedness is 12.36. On the ITS Journal Score it ranks #607 of 62,158 ranked journals.
Key figures
Citations are those received so far by the papers published in these years, so the most recent years have had less time to collect them. Two-year mean citedness is OpenAlex's measure of how often recent papers are cited; it is similar in idea to, but not the same as, an impact factor. Citation impact trend compares how often a journal's 2024-25 papers are cited with how often its 2021-22 papers were cited, each measured against all ranked journals' papers of the same years, so newer papers are not at a disadvantage. "Not enough papers" or "Not enough data" means fewer than 50 papers in one of the two-year periods (or fewer than 50 citations to the earlier papers). Values above +300% or below -90% are shown as "+300% or more" or "-90% or less": such extreme values come from very low citation counts for the earlier papers.
Papers and citations by year
| Year | Papers | Citations so far to that year's papers | Open-access papers |
|---|---|---|---|
| 2020 | 108 | 6,772 | 108 |
| 2021 | 137 | 8,781 | 137 |
| 2022 | 160 | 8,648 | 160 |
| 2023 | 131 | 3,610 | 131 |
| 2024 | 128 | 2,965 | 128 |
| 2025 | 133 | 917 | 133 |
What it publishes
The leading research topics of its papers (OpenAlex topic classification). Select a topic to find other journals that publish on it.
Similar journals
Ranked journals that publish on the same topics.
| Journal | Field | Score | Papers 2021–2025 | Open access |
|---|---|---|---|---|
| Journal of Immunotherapy | Medicine | 69.8 | 240 | 35% |
| Journal for ImmunoTherapy of Cancer | Medicine | 83.3 | 9,771 | 100% |
| Journal of Cancer Immunology | Medicine | 48.2 | 90 | 98% |
| Cancer Immunology Immunotherapy | Immunology and Microbiology | 83.7 | 1,451 | 100% |
| Immuno-Oncology Technology | Medicine | 52.7 | 1,180 | 100% |
| Journal of Immunotherapy and Precision Oncology | Medicine | 60.4 | 151 | 100% |
| Cancer Cell | Medicine | 95.8 | 992 | 66% |
| Cancer Immunology Research | Medicine | 76.7 | 1,553 | 32% |
Compare with similar journals (side by side with the two closest journals above)
Identity and sources
- ISSN-L: 1000-467X
- Print ISSN: 1000-467X
- Electronic ISSN: 1944-446X
- Publisher: BMC
- Listed in DOAJ: Yes (checked against DOAJ)
- Crossref: ISSN found in Crossref
- OpenAlex: S4306555428
Figures come from OpenAlex (papers, citations, h-index, topics), Crossref (ISSN check) and DOAJ (open-access listing and fees). They change as records are corrected, so treat them as a dated snapshot. This page does not state whether the journal is indexed in Scopus, Web of Science or PubMed.
Questions
What is the ITS Journal Score of 癌症：英文版?
It is 86.5 out of 100, which places it #607 among ranked journals. The score combines citation impact (45%), h-index (35%) and size (20%) from open OpenAlex data.
What is the impact factor of 癌症：英文版?
This site does not publish Journal Impact Factors, which belong to Clarivate. As an open alternative, its two-year mean citedness in OpenAlex is 12.36.
Is 癌症：英文版 open access?
100% of its papers from 2021–2025 are recorded as open access, and it is listed in DOAJ.
Does 癌症：英文版 charge a publication fee?
The fee is not recorded in our data. This does not mean the journal is free; many open-access journals charge authors a fee. Check the journal's own website for its current fees.